1-ethylpyrrolidine-2-carboxylic acid | 98435-76-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-ethylpyrrolidine-2-carboxylic acid
• 英文别名: N-ethyl-proline；(RS)-1-ethylpyrrolidine-2-carboxylic acid；ethylproline；1-ethyl-DL-proline；1-ethylpyrolidine-2-carboxylic acid；1-Aethyl-DL-prolin；1-ethylpyrrolidin-1-ium-2-carboxylate
• CAS: 98435-76-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: YNXFKYXSWNIWGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  1-ethylpyrrolidine-2-carboxylic acid 在 盐酸 作用下， 生成 N-ethyl ethyl prolinate
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1958, p. 736,741

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl 2-bromo-2-(3-bromopropyl)malonate 在 水 、 苯 作用下， 生成 1-ethylpyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1958, p. 736,741

  摘要：

  DOI：

文献信息

• [EN] ARGINASE INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'ARGINASE ET PROCÉDÉS D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2019177873A1

  公开（公告）日：2019-09-19

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

  本文描述了化合物I的结构或其药用盐。化合物I作为精氨酸酶抑制剂，可用于预防、治疗或作为精氨酸酶相关疾病的治疗剂。
• [EN] METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS<br/>[FR] METHODES ET COMPOSITIONS A BASE DE NOUVEAUX COMPOSES DE TRIAZINE
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2004026844A1

  公开（公告）日：2004-04-01

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明涉及抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传递相关的炎症反应的化合物。本发明还涉及抑制平滑肌细胞增殖的化合物。特别是，本发明涉及通过调节诸如Perlecan的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• METHOD FOR PRODUCING COMPOUND HAVING DEUTERATED AROMATIC RING OR HETEROCYCLIC RING
  申请人：Shimodaira Haruki

  公开号：US20100331540A1

  公开（公告）日：2010-12-30

  A method for producing a compound having a deuterated aromatic ring or heterocyclic ring according to the invention includes heating a compound having an aromatic ring or heterocyclic ring in the presence of heavy water, a transition metal and a metal which generates deuterium. As the metal which generates deuterium, at least one metal selected from the group consisting of aluminum, magnesium, zinc, iron, lead and tin is preferred. As the transition metal, at least one metal selected from the group consisting of platinum, palladium, ruthenium and rhodium is preferred. The heating is preferably carried out by microwave irradiation.

  根据本发明，生产具有氘代芳香环或杂环的化合物的方法包括在重水、过渡金属和产生氘的金属存在下加热具有芳香环或杂环的化合物。作为产生氘的金属，优选铝、镁、锌、铁、铅和锡中的至少一种金属。作为过渡金属，优选铂、钯、钌和铑中的至少一种金属。加热最好通过微波辐射进行。
• [EN] AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS<br/>[FR] DÉRIVÉS AMINOTHIAZOLE UTILES COMME INHIBITEURS DE LA KLK1
  申请人：VANTIA LTD

  公开号：WO2011051673A1

  公开（公告）日：2011-05-05

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients which such compounds; wherein R1 to R17 and A1 are as defined herein.

  本发明提供了公式(I)的化合物：包含此类化合物的组合物；此类化合物在治疗（如哮喘或慢性阻塞性肺病（COPD））中的应用；以及使用此类化合物治疗患者的方法；其中R1至R17和A1如本文所述定义。
• [EN] PRODRUGS OF THERAPEUTIC COMPOUNDS<br/>[FR] PROMÉDICAMENTS DE COMPOSÉS THÉRAPEUTIQUES
  申请人：MYREXIS INC

  公开号：WO2012148550A1

  公开（公告）日：2012-11-01

  The present invention provides compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders such as cancers.

  本发明提供了化合物、药物组合物和包含这些化合物的药物，以及在治疗癌症等疾病和疾病的方法中使用这些化合物、组合物和药物。